Clinical trials: Diabetes Type II
Type 2 Diabetes
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-8655 in Participants With Type 2 Diabetes (MK-8655-002)
This study will assess the initial safety, tolerability, pharmacokinetics, and pharmacodynamics of MK-8655, after single and multiple daily oral administrations to participants with Type 2 Diabetes (T2DM).
- Trial name
- NCT01640873
- Testing
- MK-8655
- Volunteers
- 33 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Type 2
Improving Medication Adherence Among Underserved Patients With Type 2 Diabetes
This study evaluates a mobile phone-delivered intervention, called REACH (Rapid Education/Encouragement And Communications for Health), in supporting adults with type 2 diabetes in their self-management relative to a control…
- Trial name
- NCT02409329
- Testing
- REACH, Helpline and A1c results, REACH + FAMS
- Where
- United States
- Volunteers
- 512 people
- Sponsor
- Vanderbilt University Medical Center
Diabetes Mellitus, Type 2
GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation in Monotherapy (GETGOAL-MONO Japan LTS)
The purpose of this study is to compare the benefits and risks of lixisenatide (AVE0010) used as 2-step initiation regimen and 1-step initiation regimen in Japan, over a period of 24 weeks of treatment, followed by an extension…
- Trial name
- GETGOAL-MONO (NCT00905255)
- Testing
- Lixisenatide (AVE0010), Pen auto-injector
- Where
- Japan
- Volunteers
- 69 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 2
Managing Diabetes to Gain Opportunities for a More Active Life
The purpose of this novel patient-facing disease management intervention is to develop and test a system embedded within the electronic medical record to engage patients in personalized goal setting and chronic disease management.
- Trial name
- NCT03692208
- Testing
- My Diabetes Goal Survey and Optional Care Management
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- University of Chicago
Diabetes Mellitus, Type II
Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus (0431-020)(COMPLETED)
The purpose of this study is to determine the safety and efficacy of an investigational drug in patients with type 2 diabetes mellitus.
- Trial name
- NCT00086515
- Testing
- Sitagliptin (MK0431), Metformin, Pioglitazone
- Volunteers
- 701 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes, Comparative Effectiveness of Glycemia-lowering Medications
A Comparative Effectiveness Study of Major Glycemia-lowering Medications for Treatment of Type 2 Diabetes
The GRADE Study is a pragmatic, unmasked clinical trial that will compare commonly used diabetes medications, when combined with metformin, on glycemia-lowering effectiveness and patient-centered outcomes.
- Trial name
- GRADE (NCT01794143)
- Testing
- Sulfonylurea (glimepiride), DPP-4 inhibitor (sitagliptin), GLP-1 receptor agonist (liraglutide)
- Where
- 36 sites in United States
- Volunteers
- 7,850 people
- Sponsor
- GRADE Study Group
Type 2 Diabetes Treated With Insulin, Hypoglycemia
Reducing Treatment Risk in Older Adults With Diabetes
This study will evaluate the impact of academic detailing (evidence-based provider education) with or without patient pre-visit preparation (elicitation of values and preferences) on safe insulin de-prescribing among older…
- Conditions
- Type 2 Diabetes Treated With Insulin, Hypoglycemia, Primary Health Care, Polypharmacy
- Trial name
- RETRO-DM (NCT04585191)
- Testing
- Conversation Aid, Attention Control Educational Handout
- Where
- 4 sites in United States
- Volunteers
- 450 people
- Sponsor
- Kaiser Permanente
Prostate Specific Antigen, Asymptomatic Bacteriuria
Behavioral Economics Applications to Geriatrics Leveraging EHRs
The risks and benefits of many diagnostic approaches and treatments differ for older adults compared to middle aged adults. When diagnostic and therapeutic strategies are misapplied to older adults this can lead to increased…
- Conditions
- Prostate Specific Antigen, Asymptomatic Bacteriuria, Type 2 Diabetes Mellitus
- Trial name
- BEAGLE R21 (NCT03704389)
- Testing
- Clinical decision support
- Where
- United States
- Volunteers
- 664 people
- Sponsor
- Northwestern University
Obesity, Overweight
A Study of LY3549492 in Adults With Obesity or Overweight With Type 2 Diabetes
The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to evaluate the effects of treatment with LY3549492 compared to placebo in adult participants with obesity or who are overweight…
- Conditions
- Obesity, Overweight, Type 2 Diabetes
- Trial name
- NCT07030868
- Testing
- LY3549492
- Where
- 42 sites in United States, Argentina
- Volunteers
- 1 people
- Sponsor
- Eli Lilly and Company
Heart Failure, Type 2 Diabetes Mellitus
Effect of Sotagliflozin on Cardiovascular Events in Participants With Type 2 Diabetes Post Worsening Heart Failure (SOLOIST-WHF Trial)
Primary Objective: To compare the effect of sotagliflozin to placebo on the total occurrences of cardiovascular (CV) death, hospitalization for heart failure (HHF), and urgent visit for heart failure (HF) in hemodynamically…
- Trial name
- NCT03521934
- Testing
- Sotagliflozin
- Where
- 466 sites in United States, Argentina and 30 more
- Volunteers
- 1,222 people
- Sponsor
- Lexicon Pharmaceuticals
Type 2 Diabetes Mellitus, Chronic Kidney Disease
A Study of Autologous Renal Autologous Cell Therapy (REACT) in Patients With Diabetic Chronic Kidney Disease
The purpose of the present study is to assess the safety and efficacy of up to 2 injections of REACT given 6 months (+4 weeks) apart (maximum).
- Trial name
- NCT03270956
- Testing
- Renal Autologous Cell Therapy (REACT)
- Where
- 4 sites in United States
- Volunteers
- 10 people
- Sponsor
- Prokidney
Type 2 Diabetes Mellitus
Pharmacokinetic/Pharmacodynamic Study of MP-513 With Type 2 Diabetes Mellitus
The purpose of this study is to evaluate the effect of MP-513 on 24-h glycemic control in patients with type 2 Diabetes for 4 weeks administration.
- Trial name
- NCT01072331
- Testing
- MP-513
- Where
- Japan
- Volunteers
- 99 people
- Sponsor
- Tanabe Pharma Corporation
Diabetes Mellitus, Type 2
PROTOCOL 3: Role of the Renal Nerves in the Increase in EGP in Response to Glucosuria
Purpose/Objectives: Examining the effect of SGLT2 inhibition on EGP and plasma glucose concentration in diabetic and non-diabetic subjects after kidney transplantation (i.e.
- Trial name
- NCT03168295
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Type 2 Diabetes Mellitus
Effects of PCSK9 Inhibition by Evolocumab on Postprandial Lipid Metabolism in Type 2 Diabetes
Postprandial lipemia is highly prevalent in type 2 diabetes subjects even with normal fasting triglyceride values. Humans are mostly in a postprandial rather than in a fasting state and therefore non-fasting triglyceride values…
- Trial name
- NCT02948777
- Testing
- Evolocumab
- Where
- Finland
- Volunteers
- 14 people
- Sponsor
- Marja-Riitta Taskinen
Diabetes Mellitus, Type 2
Extension to Study 200952 to Evaluate the Long-term Safety, Tolerability and Pharmacodynamics of Albiglutide Liquid Drug Product in Type 2 Diabetes Mellitus Subjects
Albiglutide has been developed for the treatment of type 2 diabetes mellitus (T2DM) as an adjunct to diet and exercise, as monotherapy, or in combination with existing therapies and has been approved by the United States (US)…
- Trial name
- NCT02750930
- Testing
- Albiglutide, Auto-injector
- Where
- 27 sites in United States
- Volunteers
- 8 people
- Sponsor
- GlaxoSmithKline
Type 2 Diabetes
A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor
The main purpose of this study is to determine the safety and efficacy of orforglipron. Participants will have Type 2 Diabetes (T2D) and have inadequate glycemic control with insulin glargine with or without metformin and/or…
- Trial name
- ACHIEVE-5 (NCT06109311)
- Testing
- Orforglipron
- Where
- 70 sites in United States, Brazil and 4 more
- Volunteers
- 546 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
Fit 24 Technology Intervention YOUTH
The purpose of this study is to examine the effects of a goal-setting intervention that utilizes a Fitbit device and text messaging to improve physical activity and sleep in Hispanic adolescents with obesity.
- Trial name
- NCT04953442
- Testing
- Fit 24
- Where
- United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Baylor College of Medicine
Impaired Glucose Tolerance, Type 2 Diabetes
Actos Now for Prevention of Diabetes (ACT NOW)
The purpose of this study is to examine whether pioglitazone versus placebo can reduce the conversion rate of impaired glucose tolerance (IGT) to type 2 diabetes mellitus
- Trial name
- NCT00220961
- Testing
- Pioglitazone
- Where
- 8 sites in United States
- Volunteers
- 602 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Type 2 Diabetes Mellitus
Pharmacokinetics and Pharmacodynamics of MK-8245 in Participants With Type 2 Diabetes (MK-8245-012)
This study will assess the safety, tolerability, pharmacokinetics, and glucose lowering activity of MK-8245 in participants with type 2 diabetes.
- Trial name
- NCT00972322
- Testing
- MK-8245
- Volunteers
- 56 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes Mellitus
A Study of the Co-administration of Sitagliptin and Atorvastatin in Inadequately Controlled Type 2 Diabetes Mellitus (MK-0431E-211)
This two-phase study was to examine if 16 weeks of treatment with sitagliptin in combination with atorvastatin reduces hemoglobin A1C (A1C) and low density lipoprotein cholesterol (LDL-C) from baseline more than atorvastatin…
- Trial name
- NCT01477853
- Testing
- Sitagliptin, Atorvastatin, Metformin (open-label)
- Volunteers
- 166 people
- Sponsor
- Merck Sharp & Dohme LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.